参考文献/References:
[1] 《中国心血管健康与疾病报告》编写组. 《中国心血管健康与疾病报告2021》概述[J]. 中国心血管病研究，2022，20(7): 577-596.[2] 高润霖. 我国冠心病介入治疗的进展与展望[J]. 中华心血管病杂志，2019(9): 675-679.[3] WEFERLING M, HAMM C W, KIM W K. Percutaneous coronary intervention in transcatheter aortic valve implantation patients: Overview and practical management[J]. Frontiers in Cardiovascular Medicine, 2021, 8: 653768. [4] DE LUCA L, ROSANO G M C, SPOLETINI I. Post-percutaneous coronary intervention angina: From physiopathological mechanisms to individualized treatment[J]. Cardiology Journal, 2022, 29(5): 850-857. [5] SINHA A, RAHMAN H, PERERA D. Coronary microvascular disease: current concepts of pathophysiology, diagnosis and management[J]. Cardiovascular Endocrinology and Metabolism, 2021, 10(1): 22-30. [6] 张运，陈韵岱，傅向华，等. 冠状动脉微血管疾病诊断和治疗的中国专家共识[J]. 中国循环杂志，2017，32(5): 421-430.[7] PADRO T, MANFRINI O, BUGIARDINI R, et al. ESC working group on coronary pathophysiology and microcirculation position paper on "coronary microvascular dysfunction in cardiovascular disease"[J]. Cardiovascular Research, 2020, 116(4): 741-755. [8] LINDEMANN H, PETROVIC I, HILL S, et al. Biopsy-confirmed endothelial cell activation in patients with coronary microvascular dysfunction[J]. Coronary Artery Disease, 2018, 29(3): 216-222. [9] MOHAMMED S F, HUSSAIN S, MIRZOYEV S A, et al. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction[J]. Circulation, 2015, 131(6): 550-559. [10] HEUSCH G, SKYSCHALLY A, KLEINBONGARD P. Coronary microembolization and microvascular dysfunction[J]. International Journal of Cardiology, 2018, 258: 17-23. [11] KLEINBONGARD P, KONORZA T, B?E D, et al. Lessons from human coronary aspirate[J]. Journal of Molecular and Cellular Cardiology, 2012, 52(4): 890-896. [12] PALMER R M, FERRIGE A G, MONCADA S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor[J]. Nature, 1987, 327(6122): 524-526. [13] VANHOUTTE P M, SHIMOKAWA H, FELETOU M, et al. Endothelial dysfunction and vascular disease - a 30th anniversary update[J]. Acta Physiologica, 2017, 219(1): 22-96. [14] WONG W T, TIAN X Y, HUANG Y. Endothelial dysfunction in diabetes and hypertension: cross talk in RAS, BMP4, and ROS-dependent COX-2-derived prostanoids[J]. Journal of Cardiovascular Pharmacology, 2013, 61(3): 204-214. [15] HEUSCH G, BAUMGART D, CAMICI P, et al. Alpha-adrenergic coronary vasoconstriction and myocardial ischemia in humans[J]. Circulation, 2000, 101(6): 689-694. [16] HEUSCH G. The paradox of α-adrenergic coronary vasoconstriction revisited[J]. Journal of Molecular and Cellular Cardiology, 2011, 51(1): 16-23. [17] YUN J S, PARK Y M, CHA S A, et al. Progression of cardiovascular autonomic neuropathy and cardiovascular disease in type 2 diabetes[J]. Cardiovascular Diabetology, 2018, 17(1): 109. [18] LIU M, GOMEZ D. Smooth muscle cell phenotypic diversity[J]. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39(9): 1715-1723. [19] DURHAM A L, SPEER M Y, SCATENA M, et al. Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness[J]. Cardiovascular Research, 2018, 114(4): 590-600. [20] LACOLLEY P, REGNAULT V, NICOLETTI A, et al. The vascular smooth muscle cell in arterial pathology: A cell that can take on multiple roles[J]. Cardiovascular Research, 2012, 95(2): 194-204. [21] RECIO-MAYORAL A, RIMOLDI O E, CAMICI P G, et al. Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease[J]. JACC: Cardiovascular Imaging, 2013, 6(6): 660-667. [22] CALABRò P, GOLIA E, YEH E T H. CRP and the risk of atherosclerotic events[J]. Seminars in Immunopathology, 2009, 31(1): 79-94.[23] ONG P, ATHANASIADIS A, BORGULYA G, et al. High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries: The ACOVA study (Abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries)[J]. Journal of the American College of Cardiology, 2012, 59(7): 655-662. [24] BAIREY MERZ C N, PEPINE C J, WALSH M N, et al. Ischemia and no obstructive coronary artery disease (INOCA)[J]. Circulation, 2017, 135(11): 1075-1092. [25] NICCOLI G, SCALONE G, LERMAN A, et al. Coronary microvascular obstruction in acute myocardial infarction[J]. European Heart Journal, 2016, 37(13): 1024-1033. [26] TAQUETI V R, DI CARLI M F. Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review[J]. Journal of the American College of Cardiology, 2018, 72(21): 2625-2641. [27] HOFFMAN J I. A critical view of coronary reserve[J]. Circulation, 1987, 75(1 Pt 2): I6-I11.[28] DANIJELA T, JELENA D, OLGA P, et al. Assessment of coronary microcirculation with myocardial contrast echocardiography[J]. Current Pharmaceutical Design, 2018, 24(25): 2943-2949. [29] FEHER A, SINUSAS A J. Quantitative assessment of coronary microvascular function: Dynamic single-photon emission computed tomography, positron emission tomography, ultrasound, computed tomography, and magnetic resonance imaging[J]. Circulation Cardiovascular Imaging, 2017, 10(8): e006427. [30] GERBER B L, ROUSSEAU M F, AHN S A, et al. Prognostic value of myocardial viability by delayed-enhanced magnetic resonance in patients with coronary artery disease and low ejection fraction: impact of revascularization therapy[J]. Journal of the American College of Cardiology, 2012, 59(9): 825-835. [31] 关星绘，孙林. 心脏磁共振技术在冠状动脉微血管疾病中的运用进展[J]. 心血管病学进展，2020，41(4): 345-348. [32] MURTHY V L, BATEMAN T M, BEANLANDS R S, et al. Clinical quantification of myocardial blood flow using PET: Joint position paper of the SNMMI cardiovascular council and the ASNC[J]. Journal of Nuclear Medicine, 2018, 59(2): 273-293. [33] LANZA G A, CAMICI P G, GALIUTO L, et al. Methods to investigate coronary microvascular function in clinical practice[J]. Journal of Cardiovascular Medicine, 2013, 14(1): 1-18. [34] VIJAYALAKSHMI K, ASHTON V J, WRIGHT R A, et al. Corrected TIMI frame count: applicability in modern digital catheter laboratories when different frame acquisition rates are used[J]. Catheterization and Cardiovascular Interventions, 2004, 63(4): 426-432.[35] MARTíNEZ G J, YONG A S C, FEARON W F, et al. The index of microcirculatory resistance in the physiologic assessment of the coronary microcirculation[J]. Coronary Artery Disease, 2015, 26(Suppl 1): e15-e26. [36] 廖念西，刘健. 冠心病患者微循环阻力指数测定的临床意义[J]. 中国介入心脏病学杂志，2017，25(8): 461-463.[37] 中国冠状动脉血流储备分数测定技术临床路径专家共识[J]. 中国介入心脏病学杂志，2019，27(3): 121-133.[38] 张梅，张运. 冠脉内注射罂粟碱测量冠状动脉血流储备的研究[J]. 中国超声医学杂志，1998(6): 17-19.[39] VERA CRUZ P, PALMES P, BACALANGCO N. Prognostic value of myocardial blush grade in ST-elevation MI: A systematic review and Meta-analysis[J]. Interventional Cardiology, 2022, 17: e10. [40] PORTO I, BURZOTTA F, BRANCATI M, et al. Relation of myocardial blush grade to microvascular perfusion and myocardial infarct size after primary or rescue percutaneous coronary intervention[J]. American Journal of Cardiology, 2007, 99(12): 1671-1673.